Publications

ZW191
AACR
April 8, 2024
ZW191 – a FRα-targeting antibody-drug conjugate with strong preclinical activity across multiple FRα-expressing indications
Lawn et al.
Preclinical
Molecular Cancer Therapeutics
February 14, 2024
Design and evaluation of ZD06519, a novel camptothecin payload for antibody drug conjugates
Petersen et al.
Preclinical
PepTalk
January 17, 2024
Engineering a Pure and Stable Heterodimeric IgA for the Development of Multispecific Therapeutics
Meghan Verstraete
Preclinical
SITC
November 4, 2023
TriTCE Co-Stim: A novel trispecific T cell engager platform, with integrated CD28 costimulation, engineered to widen the therapeutic window for treatment of poorly infiltrated tumors
Newhook et al.
Preclinical
SITC
November 4, 2023
TriTCE CPI: a novel trispecific T cell engager platform with integrated PD-1/PD-L1 checkpoint inhibition engineered for the treatment of immunosuppressed tumors
Verstraete et al.
Zanidatamab
ESMO World GI Congress
October 23, 2023
Zanidatamab (ZW25), a HER2-Targeted Bispecific Antibody, in Combination With Chemotherapy and Tislelizumab in Patients With Advanced HER2-Positive Gastric/Gastroesophageal Junction Adenocarcinoma: Updated Results From a Phase 1b/2 Study
Keun-Wook Lee, et al.
Preclinical
World ADC San Diego
October 18, 2023
ZW220 – A Potential First-in-Class TOPO1i ADC for the Treatment of NaPi2b-Expressing Solid Tumors​ 
Andrea Hernández Rojas
Preclinical
World ADC San Diego
October 16, 2023
ZW251 – A novel glypican-3 targeting ADC bearing a topoisomerase I inhibitor payload
Laurence Madera
Clinical
AACR-EORTC-NCI
October 13, 2023
Phase 1 Study of Zanidatamab Zovodotin (ZW49): Safety Profile and Recommended Dose (RD) in Patients with Human Epidermal Growth Factor 2 (HER2)-positive Solid Cancers
Preclinical
AACR-EORTC-NCI
October 12, 2023
Refining our understanding of ADCs: Drug development insights from 40 years of data
Raffaele Colombo
Preclinical
Festival of Biologics
October 10, 2023
TOPO1i ADC Platform From Concept to Pipeline Application
Mark Petersen
Preclinical
World Bispecific Summit
October 2, 2023
Engineering Trispecific T-cell Engagers to Address Biological Challenges in the Treatment of Solid Tumors
Nina Weisser